TREACE MEDICAL CONCEPTS, INC. TMCI 深 滬
等待開盤 12-20 09:30:00 美东时间
2.57
+0.080
+3.21%
華盛通- 最 高2.61
- 今 開2.51
- 成交量 186.03万股
- 最 低 2.4314
- 昨 收 2.49
- 總市值 1.64亿
- 52周最高 10.79
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.4314
- 委 比 89.75%
- 總股本 6371.81万
- 歷史最高 37.17
- 量 比 2.04
- 振 幅 7.17%
- 歷史最低 2.4314
- 每 手 1
- 風險率 1.84%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
12-19 10:15
Treace Medical Enters Into New Five Year $175M Senior Secured Loan Arrangement With Credit Funds Managed By SLR Capital Partners
Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it
12-18 21:35
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
电话会总结 ｜ Treace Medical(TMCI)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Treace Medical业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **Q3 2025核心财务数据：** - 营收：5,020万美元，同比增长11% - 毛利率：79.1%，较2024年的80.1%下降1个百分点 - 净亏损：1,630万美元（每股亏损0.26美元），同比增长6%（2024年Q3净亏损1,540万美元，每股亏损0.25美元） - 调整后EBITDA亏损：260万美元，同比改善49%（2024年Q3亏损510万美元） - 运营费用：5,540万美元，同比增长8%（2024年为5,130万美元） **年初至今财务表
11-08 12:14
BTIG Downgrades Treace Medical Concepts to Neutral
BTIG analyst Ryan Zimmerman downgrades Treace Medical Concepts (NASDAQ:TMCI) from Buy to Neutral.
11-07 19:03
Treace Announces Participation in Two Upcoming Investor Conferences
<p>Treace Medical Concepts, Inc. will participate in the UBS Global Healthcare Conference on November 10, 2025, and the Stifel 2025 Healthcare Conference on November 11, 2025. The company, focused on advancing the surgical treatment of bunions, has developed innovative systems like the Lapiplasty® 3D Bunion Correction® System and Adductoplasty® Midfoot Correction System. A live webcast of the UBS fireside chat will be available on their investor ...
11-07 13:05
Treace Medical Concepts shares are trading lower after the company reported Q3 financial results and cut its FY25 sales guidance below estimates.
Treace Medical Concepts shares are trading lower after the company reported Q3 ...
11-07 05:48
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
